AstraZeneca to pay $5.52 mln to resolve U.S. SEC foreign bribery case

NEW YORK, Aug 30 (Reuters) - U.S. regulators said on Tuesday

that AstraZeneca Plc will pay $5.52 million to resolve a

foreign bribery probe into improper payments by its sales and

marketing staff to officials at state-controlled health care

providers in China and Russia.

Read more